November 2011
November 21, 2011 –
After the FDA rejects a drug from a company's pipeline, what happens with that drug? Do they just toss it out and start over, taking millions in losses or do companies have the option to make changes and still get the drug approved? What usually happens? Thanks,Shamapant
November 16, 2011 –
I have been looking around lately, and I can't seem to find a good way to analyze a pharmaceutical company. How are the drugs that the FDA may or may not approve valued? I know we have several pharmaceutical masters on the Fool, so I need help with this. This information is important to me for future analysis, and specificly to better understand my recent find:http://caps.fool.com/Blogs/forgotten-gold-ikkyu2/669403. I was hoping to better understand my probabilities, but do not limit answers to this above contingent value rights, I want to know on a wholistic fundamental valuation approach, how are a company's drugs valued and invested in? Thanks,Shamapant [more]
November 15, 2011 –
|
RELATED TICKERS: GCVRZ
To uphold my part in the Ikkyu 2 challenge this month(i think it would be a great idea to make it a monthly thing), I wanted to highlight a special situation investment that was brought up as a huge value possibility back in April by Charly Travers, in this article: [more]
RSS Headlines
Fool UK